Ventyx Biosciences (VTYX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.24 mm	28.24 mm	28.24 mm	28.24 mm	28.24 mm	28.24 mm
Cash burn (monthly)	11.50 mm	2.03 mm	10.81 mm	12.37 mm	7.75 mm	10.91 mm
Cash used (since last report)	23.71 mm	4.18 mm	22.28 mm	25.50 mm	15.98 mm	22.48 mm
Cash remaining	4.52 mm	24.06 mm	5.96 mm	2.73 mm	12.26 mm	5.75 mm
Runway (months of cash)	0.4	11.9	0.6	0.2	1.6	0.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

VTYX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	122	119	+2.5%
Opened positions	21	23	-8.7%
Closed positions	18	32	-43.8%
Increased positions	44	34	+29.4%
Reduced positions	30	38	-21.1%

13F shares	Current	Prev Q	Change
Total value	113.38 bn	130.69 bn	-13.2%
Total shares	71.30 mm	72.54 mm	-1.7%
Total puts	83.00 k	268.50 k	-69.1%
Total calls	35.30 k	221.90 k	-84.1%
Total put/call ratio	2.4	1.2	+94.3%

Largest owners	Shares	Value	Change
Deerfield Management	6.72 mm	$14.64 bn	+15.2%
Flynn James E	6.72 mm	$14.84 mm	+89.6%
NSV Investments I	6.26 mm	$15.59 mm	0.0%
BlackRock	4.91 mm	$10.71 bn	NEW
Citadel Advisors	4.46 mm	$9.71 bn	-22.6%
Vanguard	3.47 mm	$7.56 bn	+15.8%
Farallon Capital Management	3.17 mm	$6.91 bn	0.0%
Tang Capital Partners	3.10 mm	$6.11 mm	0.0%
Tang Capital Management	3.10 mm	$6.76 bn	0.0%
venBio Global Strategic Fund III	2.72 mm	$112.81 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Capital International Investors	0.00	-5.25 mm	EXIT
BlackRock	4.91 mm	+4.91 mm	NEW
BLK BlackRock	0.00	-4.77 mm	EXIT
Flynn James E	6.72 mm	+3.17 mm	+89.6%
Citadel Advisors	4.46 mm	-1.30 mm	-22.6%
Sio Capital Management	1.97 mm	+1.19 mm	+153.2%
Opaleye Management	0.00	-1.19 mm	EXIT
UBS UBS	1.20 mm	+1.18 mm	+5438.3%
Parkman Healthcare Partners	0.00	-1.16 mm	EXIT
Deerfield Management	6.72 mm	+885.93 k	+15.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VTYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jan 25	John Nuss	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	170,104	364.02 k	170,104
2 Jan 25	John Nuss	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	245,000	524.30 k	245,000
2 Jan 25	Mark S Forman	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	85,000	181.90 k	85,000
2 Jan 25	Matthew Richard Moore	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	145,000	310.30 k	145,000
2 Jan 25	Roy Gonzales	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	17,500	37.45 k	17,500
2 Jan 25	Roy Gonzales	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	109,200	233.69 k	109,200
2 Jan 25	Raju Mohan	Stock Option Common Stock	Grant	Acquire A	No	No	2.14	700,000	1.50 mm	700,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Ventyx Biosciences Q4 EPS $(0.41) Beats $(0.54) Estimate

27 Feb 25

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.54) by 24.07 percent. This is a 48.1 percent increase over losses of $(0.79) per share from

Ventyx Biosciences Announces Presentation Of Data From The Phase 2 Trial Of Allosteric TYK2 Inhibitor VTX958 In Crohn's Disease At ECCO 2025

18 Feb 25

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to

HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciencesto Neutral

14 Jan 25

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) from Neutral to Neutral.

Ventyx Announces Phase 2 Trials For VTX2735, VTX3232; Obesity Data Expected H2 2025, Parkinson's Data H1 2025; $252.9M Funding Extends To H2 2026

14 Jan 25

Press releases

From Benzinga Pro

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

10 Dec 24

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ:VTYX) on